B-Arm Medical Technologies raises INR 48M seed round led by Mudhal Partners

Tamil Nadu-based healthcare company B-Arm Medical Technologies has raised INR 48 million in a seed round led by Mudhal Partners. The funding was dated October 10, 2026. Mudhal Partners was the sole investor listed in the funding data.

What the company does

B-Arm Medical Technologies was founded by biomedical engineers Barathram and SruthiSri Chandrasekaran. The company builds science-backed care products for women across every life stage from puberty to menopause, covering:

Preconception
Pregnancy
Postpartum recovery
Breastfeeding
Menopause

Beyond women's health, the company also sells in the pulmonology and occupational therapy segments, including products for children with autism and speech difficulties.

Intellectual property and traction

The company holds more than 10 patents. It says more than 200,000 women use its products.

Why it matters for acquisition watchers

B-Arm sits at the intersection of women's health and broader medical device categories, with an IP portfolio and a stated user base that give a strategic buyer several entry points.

Life-stage coverage. Rather than a single product, the company spans preconception through menopause, which broadens the customer relationship and repeat-purchase potential.
Adjacent categories. Pulmonology and occupational therapy — including products for children with autism and speech difficulties — extend the portfolio beyond women's health.
Patent portfolio. More than 10 patents provide defensible IP in a segment where clinical backing and design matter.
Stated scale. The company reports more than 200,000 women using its products, a useful indicator of commercial reach at the seed stage.

Round summary

Company: B-Arm Medical Technologies
Headquarters: Tamil Nadu, India
Founders: Barathram and SruthiSri Chandrasekaran (biomedical engineers)
Round: Seed
Amount: INR 48 million
Date: October 10, 2026
Lead investor: Mudhal Partners
Other investors: None disclosed

What to watch

With a seed round led by Mudhal Partners, the next milestones to track are how B-Arm converts its patent portfolio and stated user base into broader distribution across its women's health, pulmonology and occupational therapy lines. For acquirers, the company's multi-category footprint and IP position make it a candidate to monitor as it scales beyond the seed stage.